Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Although exploratory, the analyses were methodologically sound, with consistent results across renal risk categories and objective outcome ascertainment, leading to an overall moderate risk of bias and moderate-certainty evidence
In light of glucagons ability to increase glucose production, and the documented beneficial effects of glucagon signal inhibition for the treatment of type 2 diabetes, at first glance it seems counter-intuitive that glucagon could be used in unimolecular combinations with GLP-1 to treat obesity and type 2 diabetes [114]
Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al
Beyond metabolic disease, these multifunctional agonists have the potential to treat diseases where targeted medicinal action is preferred over systematic administration, as demonstrated with the GLP-1/oestrogen conjugate
Bad news
